Johns Hopkins surgeon and writer Martin Makary is expected to be selected by President-elect Donald Trump to head the U.S. FDA, Reuters’ Stephanie Kelly and Nathan Layne report, citing two sources familiar with the matter. Makary raised concerns about a number of public health issues during the Covid-19 pandemic, touting the protection from natural immunity and opposing Covid vaccine mandates. As FDA commissioner, Makary would report to the head of the Department of Health and Human Services, Reuters says, noting that Trump has nominated noted vaccine skeptic Robert F. Kennedy Jr. to head Health and Human Services. Names in the vaccine space include Moderna (MRNA), BioNTech (BNTX), Pfizer (PFE), Novavax (NVAX) and GSK (GSK).
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRNA:
- SPY ETF Update, 11/22/2024
- QQQ ETF Update, 11/21/2024
- Is Investing in Moderna Stock (NASDAQ:MRNA) Simply Dead Money?
- VOO ETF Update, 11/20/2024
- Workday initiated, Kraft Heinz downgraded: Wall Street’s top analyst calls
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
